)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Viking Therapeutics
Viking Therapeutics (VKTX) investor relations material
Viking Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
VK2735 advanced across four Phase 3 obesity studies: subcutaneous VANQUISH trials were fully enrolled, and oral SUNRISE trials began; Part 1 maintenance results were positive and Part 2 started.
Cash, cash equivalents and short-term investments totaled $960M at September 30, 2026, following September public offerings; available funds were expected to support operations through at least December 31, 2027.
Financial highlights
Q3 2026 R&D expense was $166.8M vs. $90.0M YoY; G&A was $20.3M vs. $8.6M.
Q3 net loss was $183.2M, or $1.55/share, vs. $90.8M, or $0.81/share; operating loss was $187.1M vs. $98.6M.
9M 2026 R&D expense was $432.7M vs. $191.5M; G&A was $51.1M vs. $37.1M YoY.
9M net loss was $469.5M, or $4.03/share, vs. $202.0M, or $1.80/share; 9M operating cash use was $377.3M.
No revenue was generated; higher clinical, manufacturing, compensation, legal and consulting costs contributed to increased expenses.
Outlook and guidance
VANQUISH extension periods are expected to begin in early 2027; top-line results were expected in H2 2027 per Q&A.
SUNRISE studies evaluate once-daily oral VK2735 for 68 weeks, targeting 560 participants each; dose arms are 27.5, 35 and 55 mg, with enrollment underway.
VK3019 single-ascending-dose study was expected to complete in Q4 2026, followed by a four-week multiple-ascending-dose study planned for Q1 2027.
Part 2 maintenance results are expected in 2027; the study tests daily oral and less-frequent subcutaneous dosing after weekly induction.
Losses and R&D and G&A expenses are expected to increase as programs and infrastructure advance; average cash use was expected at ~$100M per quarter, with variation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Viking Therapeutics
- VK2735 showed durable weight loss with less-frequent dosing as obesity Phase 3 trials advance.VKTX
Corporate presentation - Up to 22% weight loss and 97% maintenance achieved with flexible, well-tolerated VK2735 dosing.VKTXStudy result
- Obesity program VK2735 advances in phase III with broad market and manufacturing strategies.VKTXMorgan Stanley 24th Annual Global Healthcare Conference
- VK2735 delivers up to 14.7% mean weight loss in Phase 2, with Phase 3 trials fully enrolled.VKTXCorporate presentation
- Phase III obesity trials fully enrolled; net loss rose as R&D spending surged, with $502M in cash.VKTXQ2 2026
- VK2735 delivers up to 15% weight loss in late-stage trials with strong safety and cash reserves.VKTXCorporate presentation
- Q3 net loss rose to $90.8M as R&D spending surged; cash reserves remain strong at $715M.VKTXQ3 2025
- Strong clinical progress and $930M cash position support advancement to late-stage trials.VKTXQ3 2024
- Strong clinical progress and $903M cash position support late-stage trials in 2025.VKTXQ4 2024
Next Viking Therapeutics earnings date
Stifel 2026 Healthcare Conference 202611 Nov, 2026
Viking Therapeutics
Next Viking Therapeutics earnings date
Stifel 2026 Healthcare Conference 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company utilizes small-molecule drug technology to target conditions such as liver diseases, muscle disorders, and other chronic illnesses. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.